Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4th Quarter of 2019 – - December 2018 Interim Update of 34 efficacy evaluable patients demonstrated 32.4%...
-
EXTON, Pa., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on...
-
EXTON, Pa., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18, 2018. Ms....
-
- 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control - - Tumor shrinkage observed in both injected and uninjected lesions,...
-
EXTON, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug...
-
– Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 –– Cash runway into first quarter of 2020 – EXTON, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals,...
-
- Key findings presented in poster discussion demonstrate clear abscopal effect of intratumoral tilsotolimod - - Data demonstrate contribution of tilsotolimod to overcome resistance to ipilimumab in...
-
EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...
-
- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors - - Chief Financial Officer Louis J. Arcudi III departing the company related to company consolidation to...
-
EXTON, Pa., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune...